Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Feb;14(1):172-179.
doi: 10.1111/iwj.12578. Epub 2016 Mar 10.

Povidone-iodine ointment demonstrates in vitro efficacy against biofilm formation

Affiliations

Povidone-iodine ointment demonstrates in vitro efficacy against biofilm formation

Matthias J Hoekstra et al. Int Wound J. 2017 Feb.

Abstract

Anti-infectives used to treat chronic exuding wounds are diluted by wound exudates, absorbed into dressings, metabolised by proteases and destroyed by pH. In order to mimic such effects of exudates, the efficacy of six topical wound agents was assessed undiluted and at 10% concentrations, including povidone-iodine ointment and a silver-impregnated wound dressing, to remove biofilms of Pseudomonas aeruginosa, multi-species biofilms of Candida albicans and methicillin-resistant Staphylococcus aureus (MRSA) in vitro in a Centers for Disease Control and Prevention (CDC) reactor. Povidone-iodine was also diluted to 3·3% and 33·3% of the commercial concentrations. Viable microorganisms in each preparation were quantified by colony count. No viable P. aeruginosa biofilm material was recovered after 4 and 24 hours of treatment with povidone-iodine ointment at the 100% and 10% concentrations. No C. albicans/MRSA biofilm material was recovered after 4 and 24 hours of treatment with povidone-iodine ointment at the 100% concentration. In general, following dilution, povidone-iodine ointment appeared to exhibit greater biofilm removal than the other agents tested. Further research involving different microorganisms in vitro and in vivo over a longer period of time will help elucidate the full potential of povidone-iodine ointment and liposomal hydrogel.

Keywords: Biofilm; Candida albicans; Methicillin-resistant Staphylococcus aureus (MRSA); Povidone-iodine ointment (PVP-I); Pseudomonas aeruginosa.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Quantity of viable Pseudomonas aeruginosa recovered from coupons following 4‐hour treatment with all agents, at the commercial concentrations (100%) and at 10% of the commercial concentration. Silver dressing was tested at 100% only. MUP, mupirocin; FUA, fusidic acid; BNP, bacitracin, neomycin, and polymyxin B; PHB, polyhexanide/betaine; OCT, octenidine dihydrochloride; PVP‐I, povidone‐iodine ointment; PVP‐ILH, PVP‐I liposomal hydrogel; CHG, chlorhexidine gluconate; PBS, phosphate buffer solution.
Figure 2
Figure 2
Quantity of viable Pseudomonas aeruginosa recovered from coupons after 24‐hour treatment with all agents, at the commercial concentrations (100%) and at 10% of the commercial concentration. Silver dressing was tested at 100% only. MUP, mupirocin; FUA, fusidic acid; BNP, bacitracin, neomycin, and polymyxin B; PHB, polyhexanide/betaine; OCT, octenidine dihydrochloride; PVP‐I, povidone‐iodine ointment; PVP‐ILH, PVP‐I liposomal hydrogel; CHG, chlorhexidine gluconate; PBS, phosphate buffer solution.
Figure 3
Figure 3
Quantity of viable Candida albicans/MRSA recovered from coupons following 4‐hour treatment with all agents, at the commercial concentrations (100%) and at 10% of the commercial concentration. Silver dressing was tested at 100% only. The 33% and 3·3% concentrations of PVP‐I are also presented. MRSA, methicillin‐resistant Staphylococcus aureus; MUP, mupirocin; FUA, fusidic acid; BNP, bacitracin, neomycin, and polymyxin B; PHB, polyhexanide/betaine; OCT, octenidine dihydrochloride; PVP‐I, povidone‐iodine ointment; PVP‐ILH, PVP‐I liposomal hydrogel; CHG, chlorhexidine gluconate; PBS, phosphate buffer solution.
Figure 4
Figure 4
Quantity of viable Candida albicans/MRSA recovered from coupons after 24‐hour treatment with all agents, at the commercial concentrations (100%) and at 10% of the commercial concentration. Silver dressing was tested at 100% only. The 33% and 3·3% concentrations of PVP‐I are also presented. MRSA, methicillin‐resistant Staphylococcus aureus; MUP, mupirocin; FUA, fusidic acid; BNP, bacitracin, neomycin, and polymyxin B; PHB, polyhexanide/betaine; OCT, octenidine dihydrochloride; PVP‐I, povidone‐iodine ointment; PVP‐ILH, PVP‐I liposomal hydrogel; CG, chlorhexidine gluconate; PBS, phosphate buffer solution.
Figure 5
Figure 5
Quantity of viable Candida albicans/MRSA recovered from coupons after 4‐hour treatment with PVP‐I at standard concentration and different percentage concentrations. PVP‐I, povidone‐iodine ointment.
Figure 6
Figure 6
Quantity of viable Candida albicans/MRSA recovered from coupons after 24‐hour treatment with PVP‐I at standard concentration and different percentage concentrations. PVP‐I: povidone‐iodine ointment.

Similar articles

Cited by

References

    1. Crovetti G, Martinelli G, Issi M, Barone M, Guizzard M, Campanati B, Moroni M, Carabelli A. Platelet gel for healing cutaneous chronic wounds. Transfus Apher Sci 2004;30:145–51. - PubMed
    1. Falanga V. The chronic wound: impaired healing and solutions in the context of wound bed preparation. Blood Cells Mol Dis 2004;32:88–94. - PubMed
    1. Bryant RA, Nix DP. Acute and chronic wounds: current management concepts, 4th edn. Mosby, Elsevier, 2011.
    1. Dow G, Browne A, Sibbald RG. Infection in chronic wounds: controversies in diagnosis and treatment. Ostomy Wound Manage 1999;45:23–7, 29–40; quiz 41–2. - PubMed
    1. Kingsley A. The wound infection continuum and its application to clinical practice. Ostomy Wound Manage 2003;49(Suppl. 7A):1–7. - PubMed

MeSH terms